What were the key drivers of Johnson & Johnson's sales growth in Q1 2005?

Sales growth was driven by broad-based performance across all three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. International sales experienced particularly strong growth due to favorable currency movements and double-digit increases in Europe, the Western Hemisphere (excluding the U.S.), and Asia-Pacific, Africa regions. Specific product successes like SPLENDA, TYLENOL, RISPERDAL, REMICADE, and the CYPHER Sirolimus-eluting Stent also contributed significantly.

How did profitability change compared to the previous year?

Profitability saw a substantial improvement. Net earnings increased by approximately 17.4% to $2.9 billion from $2.5 billion in the first quarter of 2004. Diluted earnings per share also increased to $0.97 from $0.83, reflecting higher sales and improved cost management, including a decrease in the cost of products sold as a percentage of sales.

What is the status of the proposed acquisition of Guidant Corporation?

The acquisition of Guidant Corporation remains on track, with Johnson & Johnson actively responding to information requests from the U.S. Federal Trade Commission and the European Union as part of their respective review processes. The transaction is subject to customary closing conditions and antitrust clearances, with an expected closing in the third quarter of 2005.

Are there any significant legal proceedings or potential liabilities impacting the company?

Johnson & Johnson is involved in various legal proceedings, including product liability cases and patent litigation. Notably, the company is resolving cases related to the drug Propulsid, with a settlement agreement becoming effective in March 2005. While the company believes its accruals and insurance are adequate for potential liabilities, the ultimate outcome of litigation cannot be estimated with certainty and could impact results in a specific reporting period.

JNJ 10-Q Quarterly Report Q2 FY2005 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported strong first-quarter 2005 results, with worldwide sales increasing by 11.0% to $12.8 billion, driven by broad-based growth across its Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments. International sales showed particularly robust growth at 20.1%, aided by favorable currency exchange rates and strong performance in Europe and Asia-Pacific. Net earnings increased to $2.9 billion, or $0.98 per diluted share, up from $2.5 billion, or $0.84 per diluted share, in the prior year's first quarter. This marks a significant increase in profitability and reflects the company's effective operational management and product portfolio. The company also announced an increase in its quarterly cash dividend, underscoring its commitment to returning value to shareholders. The proposed acquisition of Guidant Corporation remains on track for a Q3 2005 close, subject to regulatory approvals, and is expected to be a significant strategic move for the company.

Key Highlights

1Worldwide sales increased 11.0% to $12.8 billion, driven by strong performance across all segments.
2Net earnings rose to $2.9 billion ($0.98/share) from $2.5 billion ($0.84/share) in the prior year.
3International sales grew 20.1%, outpacing U.S. sales growth of 4.9%, with significant contributions from Europe and Asia-Pacific.
4The Medical Devices and Diagnostics segment experienced strong operational growth of 13.4%, led by DePuy and Cordis.
5The Pharmaceutical segment saw a 7.0% sales increase, with notable growth in Risperdal and Remicade, though Procrit faced competitive pressures.
6The company declared an increased quarterly cash dividend, signaling confidence in future performance and commitment to shareholder returns.
7The pending acquisition of Guidant Corporation is progressing, with regulatory reviews underway and an expected closing in Q3 2005.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Apr 3, 2005

Summary

Key Highlights

Frequently Asked Questions